The revision is a step toward finalizing the transition from Paxlovid's emergency use authorization to its new drug application label, initiated in late 2023.
Commentary Recently, revelations by outstanding artist and writer/researcher/investigator Sasha Latypova about COVID genetic vaccines have shed light on the shady, ...